ALEC: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-105,662	-70,995
Depreciation and amortization	4,550	3,313
Stock-based compensation	21,815	15,413
Amortization of premiums and accretion of discounts on marketable securities	5,333	3,785
Amortization of right-of-use assets	2,852	1,757
Amortization of debt discount and debt issuance costs	215	140
Impairment of right-of-use assets and leasehold improvements	1,151	1,151
Prepaid expenses and other current assets	-2,143	478
Other assets	-73	-50
Accounts payable	2,542	2
Accrued liabilities and accrued clinical supply costs	-13,993	-16,507
Payable to collaboration partner	4,874	693
Deferred revenue	-14,808	-11,548
Refund liability to collaboration partner	38,104	26,063
Lease liabilities	-4,865	-3,182
Other long-term liabilities	210	210
Net cash used in operating activities	-142,340	-109,829
Purchase of property and equipment	41	30
Purchase of marketable securities	190,831	131,879
Maturities of marketable securities	358,890	250,385
Sale of marketable secuirities	2,981	2,981
Net cash provided by investing activities	170,999	121,457
Proceeds from issuance of common stock, net of issuance costs	14,701	-
Purchase of common stock under employee stock purchase plan	122	122
Proceeds from issuance of common stock upon public offering, net of issuance costs	-	0
Net cash provided by financing activities	14,823	122
Net increase (decrease) in cash, cash equivalents, and restricted cash	43,482	11,750
Cash and cash equivalents at beginning of period	34,867	-
Cash and cash equivalents at end of period	78,349	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

ALEC: the cashflow